ECSP11011192A - Formulación de anticuerpo - Google Patents

Formulación de anticuerpo

Info

Publication number
ECSP11011192A
ECSP11011192A EC2011011192A ECSP11011192A ECSP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC 2011011192 A EC2011011192 A EC 2011011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
antibody
formulation
novel pharmaceutical
agglomerates
Prior art date
Application number
EC2011011192A
Other languages
English (en)
Inventor
Hans Joachim Wallny
Joachim Momm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011192A publication Critical patent/ECSP11011192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a novedosas formulaciones farmacéuticas, en particular a novedosas formulaciones farmacéuticas en donde el ingrediente activo comprende anticuerpos humanos para la interleucina-1-beta humana (IL-1ß), en particular el anticuerpo ACZ885, y a formulaciones farmacéuticas que son estables y están libres de aglomerados después de su almacenamiento y suministro.
EC2011011192A 2008-12-10 2011-07-08 Formulación de anticuerpo ECSP11011192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
ECSP11011192A true ECSP11011192A (es) 2011-08-31

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011192A ECSP11011192A (es) 2008-12-10 2011-07-08 Formulación de anticuerpo

Country Status (31)

Country Link
US (3) US20110236398A1 (es)
EP (4) EP2196476A1 (es)
JP (6) JP6143416B2 (es)
KR (2) KR20170044211A (es)
CN (3) CN114225022A (es)
AU (1) AU2009324371B2 (es)
BR (1) BRPI0922730A2 (es)
CA (1) CA2745938C (es)
CL (1) CL2011001406A1 (es)
CO (1) CO6361952A2 (es)
CY (2) CY1117735T1 (es)
DK (2) DK2376533T3 (es)
EC (1) ECSP11011192A (es)
ES (2) ES2579835T3 (es)
HR (2) HRP20211899T1 (es)
HU (2) HUE056626T2 (es)
IL (3) IL264316B2 (es)
LT (1) LT3072906T (es)
MA (1) MA33023B1 (es)
MX (1) MX2011006242A (es)
MY (2) MY157772A (es)
NZ (1) NZ592918A (es)
PE (1) PE20120342A1 (es)
PL (2) PL3072906T3 (es)
PT (2) PT2376533T (es)
RU (2) RU2745601C2 (es)
SI (2) SI3072906T1 (es)
SM (1) SMT201600222B (es)
TN (1) TN2011000229A1 (es)
WO (1) WO2010066762A1 (es)
ZA (1) ZA201103362B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
KR20190047135A (ko) 2010-03-01 2019-05-07 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
LT4108671T (lt) 2010-10-01 2025-01-10 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
KR102213535B1 (ko) * 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN109999195A (zh) * 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2968538A1 (en) 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
JP2017527560A (ja) * 2014-09-03 2017-09-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 安定抗ｉｌ−４ｒアルファ抗体配合物
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US11058769B2 (en) 2015-12-07 2021-07-13 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
SMT202100317T1 (it) * 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
EP3487584A1 (en) * 2016-07-21 2019-05-29 Novartis AG Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
EP3518891A1 (en) * 2016-09-27 2019-08-07 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc. novo fragmento fab do anticorpo muc1 anti-humano
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
MX2020002813A (es) * 2017-09-13 2020-07-21 Novartis Ag Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
CA3094934A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
MY205764A (en) 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PL208069B1 (pl) 2000-06-29 2011-03-31 Abbott Lab Sposób uzyskiwania przeciwciała o podwójnej specyficzności lub jego części wiążącej antygen
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1610820B2 (en) * 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
AU2006207901A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ES2707284T3 (es) * 2005-03-08 2019-04-03 Pfizer Prod Inc Composiciones de anticuerpo anti-CTLA-4
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
KR101749388B1 (ko) 2005-10-26 2017-06-20 노파르티스 아게 Ｉｌ-1베타 화합물의 신규 용도
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
PL3072906T3 (pl) 2022-01-24
EP2376533A1 (en) 2011-10-19
SMT201600222B (it) 2016-08-31
DK3072906T3 (da) 2021-12-13
MA33023B1 (fr) 2012-02-01
CO6361952A2 (es) 2012-01-20
HRP20211899T1 (hr) 2022-03-04
HRP20160754T1 (hr) 2016-08-12
KR101762966B1 (ko) 2017-07-31
JP7286595B2 (ja) 2023-06-05
CN102245639B (zh) 2014-12-24
CA2745938A1 (en) 2010-06-17
EP2376533B1 (en) 2016-03-30
ES2900624T3 (es) 2022-03-17
IL264316B1 (en) 2023-09-01
MY166050A (en) 2018-05-22
JP2012511540A (ja) 2012-05-24
AU2009324371B2 (en) 2013-10-10
JP6143416B2 (ja) 2017-06-07
PE20120342A1 (es) 2012-04-24
JP2015231997A (ja) 2015-12-24
CY1124844T1 (el) 2022-11-25
KR20170044211A (ko) 2017-04-24
CN104399076B (zh) 2021-09-14
SI2376533T1 (sl) 2016-07-29
US20120315285A1 (en) 2012-12-13
CN104399076A (zh) 2015-03-11
DK2376533T3 (en) 2016-06-27
SI3072906T1 (sl) 2022-01-31
CN102245639A (zh) 2011-11-16
RU2563179C2 (ru) 2015-09-20
JP2026021446A (ja) 2026-02-10
US8623367B2 (en) 2014-01-07
CL2011001406A1 (es) 2012-03-30
IL212922A0 (en) 2011-07-31
RU2011127913A (ru) 2013-01-20
IL264316A (en) 2019-02-28
CY1117735T1 (el) 2017-05-17
TN2011000229A1 (en) 2012-12-17
HK1159130A1 (zh) 2012-07-27
RU2745601C2 (ru) 2021-03-29
ZA201103362B (en) 2012-01-25
RU2015132431A3 (es) 2018-12-24
EP2196476A1 (en) 2010-06-16
JP2023109938A (ja) 2023-08-08
CA2745938C (en) 2018-04-24
IL264316B2 (en) 2024-01-01
CN114225022A (zh) 2022-03-25
EP3792282A1 (en) 2021-03-17
IL276622A (en) 2020-09-30
ES2579835T3 (es) 2016-08-17
HUE056626T2 (hu) 2022-02-28
JP2020203889A (ja) 2020-12-24
JP2018168158A (ja) 2018-11-01
LT3072906T (lt) 2021-12-27
RU2015132431A (ru) 2018-12-24
PT3072906T (pt) 2021-12-14
IL212922B (en) 2019-02-28
PT2376533T (pt) 2016-07-13
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
PL2376533T3 (pl) 2016-09-30
AU2009324371A1 (en) 2011-06-23
EP3072906A1 (en) 2016-09-28
WO2010066762A1 (en) 2010-06-17
EP3072906B1 (en) 2021-09-08
HUE028408T2 (en) 2016-12-28
KR20120009421A (ko) 2012-01-31
BRPI0922730A2 (en) 2018-11-06
US20200384108A1 (en) 2020-12-10
MX2011006242A (es) 2011-06-24
US20110236398A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
ECSP11011192A (es) Formulación de anticuerpo
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
AR111455A1 (es) Formulación estable de anticuerpo
CL2015001959A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
AR079556A1 (es) Formacion de anticuerpos
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2013002597A (es) Arilpirrolidinas pesticidas.
EP2799543A4 (en) HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
CO7101240A2 (es) Compuestos ß-lactámicos sustituidos con amidina, su preparación y uso como agentes bacterianos
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
NZ705109A (en) Antibody formulations and uses thereof
MX382443B (es) Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
MX357936B (es) Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente.
ECSP13012666A (es) Formulacion en comprimidos difusibles y flotantes de un pesticida
MX385093B (es) Formulaciones de espuma y aparatos para su suministro.
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
UY33822A (es) Combinaciones de compuestos activos ectoparasiticidas
BR112013009415A2 (pt) composto de éter arilóxidihalo-propenil e uso destes
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
CL2015003191A1 (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas